The raised guidance and accelerating BRUKINSA growth signal strong commercial momentum. Watch for the potential reversal of valuation allowances in Q4 2026, which could produce a material tax benefit. Also monitor upcoming ASH 2026 data readouts for BRUKINSA MANGROVE and tacabrutideg.
Drugs in focus
ONC drug pipeline →Ziihera
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
- Next catalyst
- None dated
What to watchZiihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $387.25entry
- T+1 · 11d ago +5.09%α +4.78% · $406.96
- T+5 · 5d ago +7.41%α +4.12% · $415.96
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BeOne Medicines reported Q3 2026 total revenue of $1.89B (+34% YoY) and GAAP diluted EPS of $3.28 (+201% YoY), both well above consensus estimates of $1.76B and $1.88. The company raised its full-year 2026 revenue guidance to $6.9B-$7.0B from $6.6B-$6.8B and lifted GAAP operating income guidance to $1.2B-$1.3B. BRUKINSA global sales reached $1.4B (+34% YoY), driven by U.S. growth of 36%.
Key Financial Metrics
Key Facts
- Total revenue $1.89B, +34% YoY, above $1.76B consensus
- GAAP diluted EPS $3.28, +201% YoY, above $1.88 consensus
- Non-GAAP diluted EPS $4.59, +73% YoY
- BRUKINSA global sales $1.4B, +34% YoY; U.S. sales $1.0B, +36% YoY
- Full-year 2026 revenue guidance raised to $6.9B-$7.0B from $6.6B-$6.8B
- GAAP operating income guidance raised to $1.2B-$1.3B from $1.0B-$1.1B
- GAAP net income $385M, +208% YoY
- Free cash flow $474M, +34% YoY
- Gross margin 88% GAAP, 90% adjusted, up from 86% prior year
Financial Impact
Revenue beat consensus by $130M (7.4%); EPS beat by $1.40 (74.5%); guidance raised by $300M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| BRUKINSA | $1.4B | +34.0% |
| TEVIMBRA | $243.0M | +28.0% |
| Amgen in-licensed products | $167.0M | +26.0% |
Risk Factors
- R&D and SG&A expenses continue to grow (19% and 12% YoY respectively), pressuring margins
- Non-cash intangible asset impairment of $22M from discontinuing POBEVCY promotion
- Foreign exchange exposure; guidance assumes Nov 1, 2026 rates
- Document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070469 |
| Document: bgne-20261105.htm | 0001628280-26-070469 |
| Document: 0001628280-26-070469-index-headers.html | 0001628280-26-070469 |
| Document: 0001628280-26-070469-index.html | 0001628280-26-070469 |
| Document: 0001628280-26-070469.txt | 0001628280-26-070469 |
| 8-K Data (Synthetic) | 0001628280-26-070469 |
Track record
27 reports on ONC
2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers